Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 6:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Mood, Anhedonia, Depression
Interventions: Behavioral Activation plus Savoring, Empathic Listening; Behavioral
Lead sponsor: Southern Methodist University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Primary Vitreoretinal Lymphoma
Interventions: ICM ADX-2191 injection, Monthly ADX-2191 injection; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acne Vulgaris
Interventions: Vehicle, Tazarotene Cream, 0.1 %, Tazorac Cream, 0.1%; Drug
Lead sponsor: G & W Laboratories Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,741 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Arlington Hts., Illinois

Conditions: Hypothyroidism
Interventions: Levothyroxine Pill, Placebo; Drug
Lead sponsor: Spyridoula Maraka; Other
Eligibility: 65 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 3
States / cities: Little Rock, Arkansas • Gainesville, Florida • Rochester, Minnesota

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: Fluid Management Intervention; Other
Lead sponsor: University of Oklahoma; Other
Eligibility: Up to 12 Hours
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: New York, New York • Lawton, Oklahoma

Conditions: HIV Infections, Sexually Transmitted Diseases, Viral, Syphilis
Interventions: mLab App Plus; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 39 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: New York, New York • Nashville, Tennessee

Conditions: Gastroparesis
Interventions: Gastric Electrical Stimulator, Enterra, Medtronics, Inc.; Device
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Abdominal Surgery Patients
Interventions: Dexmedetomidine; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Timeline: 2007
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: IUD, Abnormal Uterine Bleeding, Pain, Cervical
Interventions: Carevix, Tenaculum; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Depression, Coronary Heart Disease
Interventions: Collaborative Care; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Down Syndrome
Interventions: Placebo, RG1662; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 30 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 9
States / cities: La Jolla, California • Sacramento, California • Decatur, Georgia + 6 more

Conditions: Opioid-induced Constipation
Interventions: ALKS 37, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 20
States / cities: Mesa, Arizona • Phoenix, Arizona • National City, California + 17 more

Conditions: Heart Failure, Worsening Heart Failure (WHF)
Interventions: Placebo, R2R01; Drug
Lead sponsor: River 2 Renal Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 8
States / cities: Fairhope, Alabama • Fort Meyers, Florida • Hialeah, Florida + 5 more

Conditions: Urinary Tract Infections
Interventions: Standard Latex Foley Catheter, Silver Coated Latex Foley Catheter; Device
Lead sponsor: Tyco Healthcare Group; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Anxiety Disorder, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Psychosocial Effects of Cancer and Its Treatment, Sleep Disorders, Excercise
Interventions: exercise intervention, counseling intervention, Educational Intervention, laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables, fatigue assessment and management, quality-of-life assessment, Fitness testing; Behavioral · Other · Procedure
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older
Enrollment: 889 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2026
U.S. locations: 3
States / cities: Detroit, Michigan • Lebanon, New Hampshire • Chapel Hill, North Carolina

Conditions: Dry Eye
Interventions: Brimonidine Tartrate, Placebos; Drug
Lead sponsor: Ocugen; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 16
States / cities: Newport Beach, California • Rancho Cordova, California • Pompano Beach, Florida + 11 more

Conditions: Acute-graft-versus-host Disease
Interventions: AAT, Placebo; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 12 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 12
States / cities: Scottsdale, Arizona • St. Petersburg, Florida • Atlanta, Georgia + 9 more

Conditions: Fibromyalgia
Interventions: Percutaneous electrical nerve field stimulation; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Vulvovaginal Atrophy, Menopause, Dyspareunia
Interventions: Estradiol Vaginal Capsule (EVC), Placebo; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 20
States / cities: Tucson, Arizona • San Diego, California • New London, Connecticut + 17 more

Conditions: Hepatitis C Virus Infection
Interventions: LDV/SOF, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: End Stage Renal Disease
Interventions: Empagliflozin 10 MG, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Sleep, Mood, Cognitive Performance
Interventions: Proprietary Spearmint Extract Blend, Control; Dietary Supplement · Other
Lead sponsor: University of Arizona; Other
Eligibility: 22 Years to 50 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Alzheimer Disease
Interventions: Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers, Blood Biomarkers, Rating Scales, PU-AD, Placebo; Radiation · Diagnostic Test · Behavioral + 1 more
Lead sponsor: Samus Therapeutics, Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Boca Raton, Florida • Delray Beach, Florida • Lake Worth, Florida + 6 more

Conditions: COVID-19
Interventions: Dapsone 85 mg PO BID, Placebo 85 mg PO BID; Drug
Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre; Other
Eligibility: 40 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Phoenix, Arizona • High Point, North Carolina • Philadelphia, Pennsylvania + 2 more

Search by objective public record fields.

Behavioral Activation Plus Savoring for University Students

A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma

Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris

Discontinuation of Low-Dose Levothyroxine in Older Adults With Subclinical Hypothyroidism

Fluid Restriction in Respiratory Distress of the Newborn

mLab App Plus: A Randomized Controlled Trial of a Mobile Health (mHealth) Intervention

Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis

Bariatric Dose-ranging Study With Dexmedetomidine

Assessing Pain and Effectiveness of Carevix Device for IUD Insertions

Depression Outpatient Cardiology Screening Study

A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)

ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)

To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

Study Comparing the DOVER Silver Foley Catheter to a Standard of Care Catheter and a Marketed Silver Coated Foley Catheter

Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

Auricular Neuromodulation in Veterans With Fibromyalgia

A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy

Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection

Safety and Efficacy of Empagliflozin in Hemodialysis

Investigational Test of a New Sleep Supplement

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19